Bharat Biotech claimed it began to work on the Zika Virus a year ago.
The company said it has invested over 150 million dollars since inception to build its portfolio of vaccines.
The most remarkable vaccine developments have been-
Rotavac - First vaccine from the developing world
Chikungunya Vaccine- entering Phase 1 trials shortly, first in the developing world.
Typbar TCV -Typhoid Conjugate Vaccine – successfully commercialized.
"The first thing is to be prepared for the worst," said Ella said who along with Sumathy and the R&D team at Bharat Biotech is working in the Zika vaccine program said.